<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42913">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547688</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00046727</org_study_id>
    <nct_id>NCT02547688</nct_id>
  </id_info>
  <brief_title>Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep</brief_title>
  <official_title>Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary data show that high flow nasal air has been shown to reduce promote heat
      exchange due to evaporation of nasal mucus by the air flow resulting in heat loss. It is
      unclear whether unidirectional nasal airflow is well tolerated in healthy individuals. The
      central hypothesis of this proposal is that dry high flow nasal air will be sufficiently
      tolerated in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Tolerability using Questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Participant response to nasal high flow using 7 point Likert scale</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Nasal High Flow</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects are in this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal High Flow</intervention_name>
    <arm_group_label>Nasal High Flow</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women

          -  Able to consent

          -  Age â‰¥ 18

          -  BMI&lt;30kg/m2

        Exclusion Criteria:

          -  Previous diagnosis of obstructive sleep apnea or sleep disorder

          -  History of Constant Positive Airway Pressure treatment for Obstructive Sleep Apnea

          -  History of recurrent epistasis

          -  Pregnancy (self-report)

          -  Deviated nasal septum

          -  Unstable cardiovascular disease (decompensated Congestive Heart Failure, myocardial
             infarction or revascularization procedures, unstable arrhythmias)

          -  Uncontrolled hypertension with BP &gt; 190/110

          -  Daytime hypoxemia with oxygen saturation&lt;90% (measured at history and physical
             examination)

          -  Supplemental oxygen use

          -  Work in transportation industry as a driver or pilot.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Kirkness, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Kirkness, PhD</last_name>
    <phone>410-550-2184</phone>
    <email>Jason.Kirkness@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Kirkness, PhD</last_name>
      <phone>410-550-2184</phone>
      <email>jason.kirkness@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Kirkness, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 10, 2015</lastchanged_date>
  <firstreceived_date>September 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Jason Kirkness</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
